China Archives

News and Trends 27 Jan 2023

HKUMed uncovers T cell exhaustion factor driving cancer immunotherapy resistance

A research team from the LKS Faculty of Medicine, the University of Hong Kong (HKUMed) has identified an unexpected driver of cancer immunotherapy resistance: the harmful effect of chronic Type…

January 27, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 11 Jan 2023

Lifesciences and biotech in 2023

A Q&A with Bill Coyle, principal, ZS. ZS is a management consulting and technology firm focused on transforming global healthcare. In some ways, 2022 could be seen as a challenging…

January 11, 2023 - 7 minutesmins - By Jim Cornall

News and Trends 9 Jan 2023

Cartherics granted first patent in China

Cartherics Pty Ltd, a biotechnology company developing immune cell therapies for the treatment of cancer, has been granted a Chinese patent, “Genetically modified cells and uses thereof.” The patent provides…

January 9, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 3 Jan 2023

Legend Biotech new drug application approved in China

Legend Biotech Corporation has announced that China’s National Medical Products Administration (NMPA) has formally accepted its new drug application (NDA) for ciltacabtagene autoleucel (cilta-cel). This submission is based on data…

January 3, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 19 Dec 2022

Jacobio’s cancer treatment given breakthrough therapy designations by China CDE

Jacobio Pharma’s in-house KRAS G12C inhibitor JAB-21822 has been granted breakthrough therapy designations in China. The designations are for the second line and above treatment of advanced or metastatic non-small…

December 19, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 5 Dec 2022

First subject dosed in inflammation phase I study

Innovent Biologics, Inc. and UNION therapeutics A/S have announced that the first Chinese healthy volunteer has been successfully dosed in the phase I study of orismilast, a potential best-in-class PDE4…

December 5, 2022 - 5 minutesmins - By Jim Cornall

News and Trends 2 Dec 2022

Tris Pharma and Pediatrix Therapeutics extend partnership for ADHD portfolio

Tris Pharma, Inc announced today (December 2) that they have expanded their partnership allowing Pediatrix Therapeutics to receive exclusive rights to commercialize its entire FDA-approved ADHD portfolio as well as ADHD pipeline…

December 2, 2022 - 2 minutesmins - By Liza Laws

News and Trends 2 Dec 2022

Full-Life Technologies acquiring Focus-X Therapeutics

Full-Life Technologies, a global radiotherapeutics company, is acquiring New Jersey-based Focus-X Therapeutics, a company developing targeted radiopharmaceuticals to treat cancer based on peptide engineering technology. The acquisition expands Full-Life’s pipeline,…

December 2, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 25 Nov 2022

XtalPi and CK Life Sciences partner on tumor vaccine R&D

XtalPi has entered into a strategic collaboration with CK Life Sciences, a member of the CK Hutchison Group. The goal is to jointly develop a novel artificial intelligence (AI) tumor…

November 25, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 24 Nov 2022

FDA gives IND approval for Ascletis Covid drug

Ascletis Pharma Inc. has revealed that the U.S. Food and Drug Administration (FDA) has approved the investigational new drug (IND) application of ASC11, an oral inhibitor drug candidate targeting 3-chymotrypsin…

November 24, 2022 - 2 minutesmins - By Jim Cornall

More News! 18 Nov 2022

Triastek cleared for 3D printed medicine treatment of ulcerative colitis

Triastek, Inc. has received clearance for its Investigational New Drug (IND) application from the United States Food and Drug Administration (FDA) to initiate clinical studies of the 3D printed medicine,…

November 18, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 17 Nov 2022

Ascletis announces IND approval for treatment of advanced solid tumors

Ascletis Pharma has announced the approval of the investigational new drug (IND) application by China National Medical Products Administration (NMPA). The approval is for an in-house developed oral PD-L1 small…

November 17, 2022 - 2 minutesmins - By Liza Laws

News and Trends 17 Nov 2022

VISEN growth hormone deficiency trial results announced

VISEN Pharmaceuticals has published detailed clinical data from its pivotal phase 3 study of lonapegsomatropin, a long-acting prodrug of unmodified somatropin being investigated as a once-weekly injection in children with…

November 17, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 16 Nov 2022

Ascletis’ monkeypox tablet receives IND approval from the FDA

A drug to treat monkeypox from Ascletis Pharma has had its investigational new drug (IND) application approved by the U.S Food and Drug Administration (FDA). The FDA made its decision…

November 16, 2022 - 3 minutesmins - By Liza Laws

News and Trends 15 Nov 2022

Biotheus enters agreement with Hansoh Pharma for bispecific antibody

Biotheus Inc., a clinical-stage biotech company focused on the discovery and development of biologics for oncology and inflammatory diseases, has entered into a collaboration agreement with Hansoh Pharmaceuticals, for Biotheus'…

November 15, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 14 Nov 2022

Nuance Pharma’s RSV vaccine cleared for trial in China

Nuance Pharma says China’s Center for Drug Evaluation (CDE) has approved its investigational new drug (IND) application supporting its pivotal phase III clinical trial of MVA-BN RSV vaccine against respiratory syncytial…

November 14, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 14 Nov 2022

HUTCHMED announces positive gastric cancer study results in China

HUTCHMED (China) Limited has announced initial results from FRUTIGA, a phase III study of fruquintinib combined with paclitaxel in 703 Chinese patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.…

November 14, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 10 Nov 2022

Ascentage Pharma gets Chinese approval for solid tumor study

Ascentage Pharma says its novel inhibitor of the embryonic ectoderm development (EED) protein, APG-5918, has been approved by the Center for Drug Evaluations (CDE) of China National Medical Products Administration…

November 10, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 8 Nov 2022

Does covid vaccination boost cancer treatment?

Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. It was feared that vaccination against Covid-19 could reduce the success of cancer…

November 8, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 7 Nov 2022

First patient dose completed for bladder cancer diagnostic drug

Asieris Pharmaceuticals says it has completed the first patient dose in its phase III bridging trial for Hexvix, a drug used for the diagnosis of bladder cancer. Asieris Pharmaceuticals is a…

November 7, 2022 - 2 minutesmins - By Jim Cornall

Report: new Frontiers in Vaccinology

Listen to our podcast

View all sectors A-Z

Register for the Webinar

View all companies A-Z

Find new scientific partnerships. Create a free IN-PART account

View all countries A-Z

Report: The European Biotech Startup Ecosystem

Subcribe to our newsletter

Learn more about Inova, the leading platform for biopharma partnering